- [Urgent Recommendation] Forget the stocks that surged so far! Capturing a jackpot stock with unprecedented good news
- Individual investors who want to rewrite their stock life from now on, be sure to apply for the free trial!
The pipeline (new drug candidate) ‘Lenzilumab’ owned by Humanigen is undergoing Phase 3 clinical trials in the US as a COVID-19 treatment. It has also started combination therapy clinical trials with ‘Yescarta’, an immune cell therapy from Kite, a subsidiary of US pharmaceutical company Gilead Sciences.
According to the Financial Supervisory Service's electronic disclosure system, KPM Tech and Telcon RF Pharmaceutical formed a consortium on June 1 and invested $4 million in Humanigen, a US new drug development company. They acquired 4,597,700 new shares of Humanigen.
KPM Tech and Telcon RF Pharmaceutical each hold 2,298,850 shares of Humanigen, with a stake of 1.10%.
In 2019, we consistently recommended: Kukbo 260% -> Kukil Paper 400% -> Playwith 510% - 3 consecutive successes!
In 2020, Access Bio 1,400% > Kakao 207% > Shinpung Pharmaceutical 2100% - 3 consecutive successes!
The stock we recommend right now is on a completely different level from the ones recommended before.
You can expect great things in the second half of 2020.
Strong performance momentum & institutional accumulation! Only absolutely undervalued stocks selected!
The robo-advisor analyzes corporate value, materials, good news, and supply-demand to time buy/sell signals.
▶ 2020’s highest performance forecast! Buy before it flies higher! ==> Click!
Any individual investor who wants to create a profit account through recommended stocks can apply!
Big jackpot stocks revealed and recommended for the second half of 2020! Don’t hesitate or you’ll be late!
[Today’s Stocks of Interest]
#KPMTech #TelconRFPharmaceutical #JinwonLifeScience #IlsinBio #SamsungElectronics
※ This content is unrelated to the editorial direction of Asia Economy, and all responsibility lies with the information provider.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

